Alfacell data shows Onconase safely eliminates cancerous cells

By Elaine Rigoli

Tampa, Fla., May 11 - Alfacell Corp. released data on the effectiveness of Onconase (ranpirnase) against non-small cell lung cancer, which indicates that Onconase induced apoptosis in apoptosis-resistant A549 human non-small lung cancer cells.

In animal studies, Onconase significantly reduced tumor hypertension, the major physiological barrier to drug delivery, the company said in a news release.

"In these studies, we used non-invasive methods to examine changes in blood flow, levels of biochemical metabolites and cellular responses in vitro and in vivo. Using a near-infrared spectroscopy method, we found significant increases in tumor perfusion, without changes in blood flow of skeletal muscles, during the first 120 minutes after treatment with Onconase," said Intae Lee, a professor in the department of radiology at the University of Pennsylvania.

"At the same time, there was approximately a 20% decrease of lactate levels, caused by the removal of tumor acidic metabolites by Onconase. ATP levels were also decreased, likely due to inhibition of QO2 in the A549 tumor cell lines."

Based in Bloomfield, N.J., Alfacell is a biopharmaceutical company focused on cancer therapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.